[Pertussis: data collection and vaccinal strategy].

UNLABELLED: Renacoq is a pediatric hospital-based surveillance network in France, set up in April 1996 to monitor the trend of pertussis among children and the impact of vaccination strategies.
METHOD: The authors studied the link between data collection and public health policy. Microbiologists from 43 hospitals notify diagnosis of pertussis among children less than 16 years of age. Pediatricians complete a questionnaire for infants less than 6 months of age fulfilling the case definitions. Positive cultures are sent to the National reference laboratory to validate biological results. Data collected from 1996 to 2007 was analyzed, as well as its interaction with changes in pertussis vaccine policy.
RESULTS: The introduction of adolescent and adult boosters was largely supported by Renacoq data but this was not the case for interruption of whole cell vaccine use. The impact of adolescent booster is moderate because of a limited vaccine coverage. There was no observed impact of the adult booster but the coverage is very weak. The introduction and then the sole use of acellular vaccine did not have any impact on Renacoq data. DISCUSSION: The study illustrates the burden of the disease among infants and the link between surveillance data collection and public health decision. It highlights the difficulty to implement new vaccine strategies and the importance of data collection, stressing the need for a better consideration of hospital practitioners involved in public healthcare surveillance.